Transformation at Eli Lilly & Co. (A) Custom Case Solution & Analysis

Evidence Brief: Eli Lilly and Co. Transformation

1. Financial Metrics

2. Operational Facts

• Current Model: Fully Integrated Pharmaceutical Company (FIPCO) where all functions from discovery to marketing are handled internally.
• Proposed Model: Fully Integrated Pharmaceutical Network (FIPNet) focusing on external partnerships and shared risk.
• R and D Pipeline: Approximately 60 molecules in clinical development as of 2009.
• Headcount Reduction: Plan to reduce workforce by 5,500 positions to lower the cost base.
• Organizational Structure: Transitioning to five Therapeutic Business Units: Oncology, Diabetes, Established Markets, Emerging Markets, and Bio-Medicines.

3. Stakeholder Positions

• John Lechleiter (CEO): Rejects the mega-merger strategy used by peers; insists on R and D productivity as the primary driver of value.
• Jan Lundberg (Head of R and D): Tasked with increasing the speed and decreasing the cost of drug development.
• Shareholders: Concerned with the impending 50 percent revenue drop and the sustainability of the dividend.
• Scientific Staff: Face uncertainty due to the shift from internal discovery to external networking.

4. Information Gaps

• Specific success rates of molecules currently in Phase 2 trials.
• Detailed breakdown of the 1 billion dollar cost reduction plan by department.
• Contractual terms and intellectual property sharing arrangements within the FIPNet partnerships.

Strategic Analysis

1. Core Strategic Question

• How can Eli Lilly replace 50 percent of its revenue base within 48 months while maintaining its identity as an independent innovation-driven firm?
• Can the organization transition from a high-fixed-cost internal model to a variable-cost network model without losing its scientific edge?

2. Structural Analysis

The pharmaceutical industry faces a structural collapse of the traditional blockbuster model. High R and D costs are no longer offset by the success rate of new molecules. The threat of generics is absolute upon patent expiry, creating a revenue valley that internal pipelines cannot fill at current speeds.

Lilly operates with a cost structure designed for a 20 billion dollar company, but it is facing a 10 billion dollar reality. The FIPCO model creates silos that slow down decision-making. Shifting to FIPNet is not an choice but a requirement for solvency.

3. Strategic Options

• Option 1: The Mega-Merger Path. Acquire a large peer (e.g., Bristol-Myers Squibb) to achieve immediate scale and cost savings.
  • Rationale: Immediate revenue replacement and massive overhead reduction.
  • Trade-offs: High risk of cultural erosion and R and D disruption.
• Option 2: The FIPNet Transformation. Dismantle the internal R and D monopoly in favor of a global network of partners.
  • Rationale: Converts fixed costs to variable costs and increases the number of shots on goal.
  • Requirements: Significant layoffs and a new capability in partnership management.
• Option 3: Diversification into Generics or Diversified Healthcare. Move into low-margin, high-volume segments.
  • Rationale: Stabilizes cash flows.
  • Trade-offs: Dilutes the focus on high-margin innovation.

4. Preliminary Recommendation

Pursue Option 2 (FIPNet). Lilly lacks the balance sheet for a successful mega-merger that would actually solve the long-term pipeline problem. The company must double down on its core competency—scientific selection—while outsourcing the execution of clinical trials and manufacturing to lower-cost regions and specialized partners.

Implementation Roadmap

1. Critical Path

• Month 1-3: Finalize the new Therapeutic Business Unit (TBU) leadership teams. Announce the 5,500-person headcount reduction to align the cost base with projected 2012 revenues.
• Month 4-12: Scale the Chorus model. This internal autonomous unit must prove it can move molecules from candidate selection to clinical proof-of-concept faster and at 20 percent of the traditional cost.
• Year 2: Transition 50 percent of clinical monitoring and data management to external providers in India and China.

2. Key Constraints

• Scientific Retention: The risk of top-tier scientists leaving during the TBU restructuring.
• Regulatory Scrutiny: Ensuring that external partners meet FDA and EMA standards for data integrity.
• Cultural Friction: Internal resistance to the Not Invented Here syndrome as the company relies more on external discovery.

3. Risk-Adjusted Implementation Strategy

The implementation must prioritize the Bio-Medicines and Oncology TBUs, as these represent the highest margin potential. A contingency fund must be maintained to restart internal programs if key FIPNet partners fail to deliver milestones. The plan assumes a 30 percent failure rate in external partnerships and builds in redundancy by multi-sourcing clinical trial management.

Executive Review and BLUF

1. BLUF

Eli Lilly must execute a radical transition from a fully integrated model to a networked innovation model to survive a 10 billion dollar revenue loss between 2011 and 2014. The strategy rejects the industry trend of mega-mergers, betting instead on a 50 percent reduction in drug development costs through the FIPNet structure. Success depends entirely on the ability of the five new Therapeutic Business Units to operate as lean, autonomous entities. The financial bridge requires 1 billion dollars in immediate cost cuts and a freeze on headcount to preserve the dividend and R and D reinvestment capacity.

2. Dangerous Assumption

The analysis assumes that the external R and D market has the capacity and quality to replace internal functions without a drop in the probability of technical success. If the networked model produces lower-quality data, the FDA approval rate will decline, making the cost savings irrelevant.

3. Unaddressed Risks

• Dividend Pressure: Maintaining the dividend while revenue drops 50 percent may starve R and D of necessary capital at the exact moment the new pipeline needs to scale.
• Partner Dependency: Lilly is trading operational control for cost flexibility. A failure at a major clinical research partner could delay the entire 2013-2014 launch schedule.

4. Unconsidered Alternative

The team did not fully evaluate a spin-off of the low-growth animal health or emerging markets businesses to generate an immediate cash infusion. This capital could be used to acquire mid-stage assets (Phase 2b) to fill the 2012-2013 revenue gap more reliably than internal discovery.

5. Verdict

APPROVED FOR LEADERSHIP REVIEW